EXCELLA Studies - Novolimus Elution from PLLA Polymer Coated Stents DESyne® and DESyne BD: Design Specifications and Clinical Updates Stefan Verheye, MD, PhD ZNA Middelheim Antwerp, Belgium On behalf of the EXCELLA investigators DESyne and DESyne BD are CE Mark Approved; Not available for sale in the U.S.

Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity Royalty Income Ownership/Founder Intellectual Property Rights Other Financial Benefit Company Names Elixir Medical

FORMULA coating technology DESyne® and DESyne® BD CE Mark-approved Polymer-Coated Workhorse DES Unique drug agent Novolimus Potent anti-proliferative with known safety profile Achieves sustained performance with the lowest drug dose (5 µcg / mm) among DES on the market Advanced Co-Cr stent platform Low profile design with ultra-thin (81 µm) struts for high flexibility and deliverability Optimal vessel wall coverage for uniform drug delivery Open cell design for ease of side branch access FORMULA coating technology Ultra-thin durable or biodegradable polymer and drug matrix coating No primer coating Lowest polymer load (<3 µm) for improved biocompatibility* Biodegradable polymer degrades into biocompatible byproducts leaving behind a true metallic stent * As reported by manufacturer

Co-Cr Stent Platform - DESyne and DESyne BD Cobalt chromium alloy stent with low strut thickness for high flexibility and deliverability Formula TM coating technology with ultra thin polymer matrix Platform features DESyne BD platform Cypher Xience / Promus Resolute BioMatrix Synergy Strut Thickness (µm) Polymer Thickness (µm) Drug Load (µg) Comparison to other leading DES* *Data on file at Elixir Medical

EXCELLA II Randomized Clinical Trial Design RANDOMIZED (2:1), SINGLE BLIND, MULTI-CENTER CLINICAL TRIAL Single/Multiple De Novo Native Coronary Artery Lesions (A-B2) Vessel Diameters: 2.5-3.5 mm Stent Diameters: 2.5-3.5 mm Lesion Length: ≤24 mm Stent Lengths: 14 - 28 mm Pre-Dilatation required / Post-Dilatation at physicians discretion Cobalt Alloy Stent + Durable Polymer + Novolimus @ 5µg per mm Stent Length ENDEAVOR Control n= 71 Geography: New Zealand, Australia, Europe and Brazil DESyne n= 139 30d 6mo 9mo 12mo 2-5yrs Clinical Follow-up Angiographic/IVUS (Subset) Follow-up Primary Endpoint: In-Stent Late Lumen Loss at 6 months (QCA) non-inferiority and superiority) Device and Procedure (Clinical) Success Key Secondary Endpoints: Device-oriented composite endpoint (Death, MI, or TLR) at 1, 6, 9, 12mo and 2-5 yrs Stent thrombosis rates at 1, 6, 9, 12mo and 2-5yrs ABR, LLL and % volume obstruction at 6 months Anti-Platelet Therapy for 12 months This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LIST MASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 5

Angiographic and IVUS Result at 9 months In-Stent Analysis DESyne NL= 154 Endeavor NL= 75 P value RVD Post-procedure (mm) 2.84±0.43 2.91±0.38 0.20 RVD At 9-months (mm) 2.82±0.44 2.70±0.42 0.06 MLD post-procedure (mm) 2.48±0.39 2.57±0.37 0.10 MLD at 9-months (mm) 2.36±0.48 1.95±0.48 < 0.001 DS (%) Post-procedure 12±5 11±5 0.34 DS (%) at 9-months 16±12 28±14 LLL at 9-months 0.11±0.32 0.63±0.42 Binary Restenosis (%) 1.4% (2/138) 7.6% (5/66) 0.037 Serial IVUS Analysis DESyne: NL = 34 Endeavor: NL = 15 % P = <0.001 Endeavor DESyne NL = Number of lesions

Primary Endpoint Analysis 9-month In-Stent Late Lumen Loss Novolimus Eluting DES 0.11 Zotarolimus 0.63 DELTA* (Upper 1-sided 95% CI) -0.54 (-0.44) Non-inferiority P value <0.001 Superiority *Least square means Zone of non-inferiority Pre-specified margin=0.20mm Zone of Superiority Zone of non-inferiority Zone of inferiority Superior -0.60 -0.50 -0.40 -0.30 -0.20 -0.10 0.00 0.10 0.20 0.30 0.40 Upper one-sided 95% CI Met Primary (Non-Inferiority) Endpoint and Superiority Endpoint

EXCELLA II 5-year Results

Conclusions The EXCELLA II Trial demonstrated both non-inferiority and superiority of the DESyne Novolimus eluting stent compared to the control Endeavor Zotarolimus eluting stent for the primary endpoint of in-stent late lumen loss at 9-months Compared to the control, the DESyne Stent demonstrated significantly greater inhibition of neointimal hyperplasia measured by IVUS at 9 months At 5 years, Target Lesion Revascularization rates were significantly lower in favour of the DESyne Stent (p=0.05) Device-oriented composite endpoints through 5 years were statistically lower for DESyne (p=0.01) All components of DoCE (cardiac death, MI and TLR) favoured the DESyne stent; stent thrombosis rates were similarly low in both arms In this study, the DESyne stent demonstrated superior neointimal inhibition while maintaining an excellent safety profile through 5 years

EXCELLA II BD Randomized Clinical Trial Design RANDOMIZED (3:1), SINGLE BLIND, MULTI-CENTER CLINICAL TRIAL Single/Multiple De Novo Native Coronary Artery Lesions (A-B2) Pre-Dilatation required / Post-Dilatation at physicians discretion Vessel Diameters: 2.5-3.5 mm Stent Diameters: Lesion Length: ≤24 mm Stent Lengths: 14 - 28 mm Cobalt Alloy Stent + Bioabsorbable Polymer + Novolimus @ 5µg per mm Stent Length DESyne BD n= 115 Geography: Belgium, Germany and Brazil ENDEAVOR Control n= 31 Clinical Follow-up Angiographic/IVUS (Subset) Follow-up 30d 6mo 9mo 12mo 2-5yrs Primary Endpoint: In-Stent Late Lumen Loss at 6 months (QCA) non-inferiority and superiority) Device and Procedure (Clinical) Success Key Secondary Endpoints: Device-oriented composite endpoint (Death, MI, or TLR) at 1, 6, 9, 12mo and 2-5 yrs Stent thrombosis rates at 1, 6, 9, 12mo and 2-5yrs ABR, LLL and % volume obstruction at 6 months Anti-Platelet Therapy for 12 months Clinical Follow-up This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LIST MASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 10

6-month Serial QCA and IVUS Results In stent QCA Analysis DESyne BD (NL = 119) Endeavor (NL = 38) P value RVD (mm) Post Procedure 3.00±0.37 3.08±0.35 0.31 6 months 2.95±0.37 2.99±0.38 0.67 MLD (mm) 2.76±0.37 2.90±0.34 0.04 2.64±0.39 2.22±0.53 <0.001 Acute gain (mm) 1.87±0.42 2.01±0.43 0.09 Late lumen Loss (mm) 0.12±0.15 0.67±0.47 < 0.001 Diameter Stenosis Post procedure 8.5±44 6.2±4.5 0.002 11.0±6.6 25.6±15.1 Binary Restenosis (%) 0.0% 7.9% 0.003 Serial IVUS Analysis DESyne BD: NL = 35 Endeavor: NL = 16 % NL : Number of lesions

Primary Endpoint Analysis Met Primary Non-inferiority Endpoint and Superiority Endpoint

DESyne BD 5-year Results Cumulative incidence of events (%) DoCE Log-Rank p= 0.771 Cardiac Death Log-Rank p= 0.335 TV-MI Log-Rank p= 0.599 CI-TLR Log-Rank p= 0.264 Elixir Endeavor

Conclusions In the EXCELLA II and EXCELLA BD trials both non-inferiority and superiority were demonstrated by the DESyne durable polymer or the DESyne BD biodegradable polymer DES as compared to the Endeavor control DES for the primary endpoint of in-stent late lumen loss at either 6 or 9 months Clinical events remained low through the final 5-year clinical follow-up demonstrating long-term clinical safety and effectiveness Clinically-indicated target lesion revascularization rates were markedly lower for both DESyne and DESyne BD as compared to the Endeavor stent through 5 years In these studies, both DESyne and DESyne BD demonstrated superior neointimal inhibition while maintaining excellent safety profiles through 5 years

Backup

Baseline Characteristics Patient Characteristics, % unless stated DESyne (N=139 ) Endeavor (N=71) Age, years (± SD) 64.7±9.6 62.7±9.7 Male 76.3% 78.9% Diabetes mellitus 23.7% 23.9% Current Smoker 15.9% 22.5% Hypercholesterolemia 85.5% 76.1% Hypertension 71.8% Previous myocardial infarction 26.6% 31.0% Previous PCI 33.8% 35.2% Unstable angina 25.2% Lesion Characteristics (QCA) (mean ± SD), or % (NL=156 ) (NL=76) AHA/ACC Lesion class B2-C 53.8% 50.7% Reference Vessel, mm (±SD) 2.74±0.48 2.74±0.47 Lesion Length, mm (± SD) 11.1±5.6 12.3±6.5 N= Number of patients NL = Number of lesions p = ns for all listed characteristics

Baseline Characteristics Patient Characteristics, % unless stated DESyne BD (N = 115) Endeavor (N = 31) Age, years (± SD) 65.0±9.3 60.4±10 Male 63.5% 77.4% Diabetes mellitus 28.7% 25.8% Current Smoker 18.3% 29.0% Hypercholesterolemia 72.2% 80.7% Hypertension 80.9% Previous myocardial infarction 25.2% 32.3% Previous PCI 20.0% Unstable angina 10.4% 9.7% Lesion Characteristics (QCA) (mean ± SD), or % (NL=127) (NL=38) AHA/ACC Lesion class B2-C 74.1% 78.9% Reference Vessel, mm (±SD) 2.94±0.38 3.01±0.46 Lesion Length, mm (± SD) 14.6±5.5 15.3±5.3